OUr Sponsors and Partners
The goal of the Helmsley Charitable Trust T1D Program is to improve the lives of all people living with type 1 diabetes (T1D). Working closely with key players across the T1D ecosystem – patients, physicians, caregivers, researchers, government agencies, funders, pharmaceutical companies, device makers, insurers, and community organizations – the Helmsley Charitable Trust seek to improve care and ultimately prevent the disease.
JDRF is leading the fight against type 1 diabetes (T1D) by funding research, advocating for policies that accelerate access to new therapies, and providing a support network for millions of people around the world impacted by T1D. Outside of the lab, JDRF pushes for increased government funding for research, and work with academia, clinicians, insurers, and regulators to get new therapies and devices to market quickly and safely.
The goal of the Human BioMolecular Atlas Program (HuBMAP) is to develop an open and global platform to map healthy cells in the human body. HuBMAP researchers are studying the connections that cells have with each other throughout the body to determine how the relationships between cells can affect the health of an individual.
The NIDDK’s mission is to conduct and support medical research and research training and to disseminate science-based information on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases, to improve people’s health and quality of life.
TrialNet is an international network of leading academic institutions, endocrinologists, physicians, scientists and healthcare teams at the forefront of type 1 diabetes (T1D) research. TrialNet offers risk screening for relatives of people with T1D and innovative clinical studies testing ways to slow down and prevent disease progression by preserving insulin production before and after diagnosis.
Adaptive Biotechnologies aims to improve people’s lives by translating the scale and precision of their adaptive immune systems into products to help diagnose, treat, and monitor disease through their immune medicine platform. Adaptive’s immune medicine platform have evolved over time to generate opportunities across life sciences research, clinical diagnostics and drug discovery.
The King’s College London T1D Research group is composed of experimental medicine researchers and clinical academics performing mechanistic and clinical studies, using qualitative, quantitative and neuroimaging techniques, and clinical trials to investigate aspects of diabetes, including mechanisms and treatment of hypoglycemia, eating disorders and appetite control.
The City of Hope Diabetes & Metabolism Research Institute aims to treat T1D in a multifaceted approach including the generation of novel immunotherapies such as T cell modulation and stem-cell based therapies. The City of Hope is also researching beta cell regeneration and replacement and seeks to prevent complications associated with T1D.
Pelican Therapeutics, of Heat Biologics, develops monoclonal antibodies and fusion protein-based therapies intended to activate the immune system.
Heat Biologics is a biopharmaceutical company focused on developing tools to activate T cells to fight against diseases. Heat Biologics uses its proprietary gp96 platform to activate immune responses to cancer and pathogenic antigens.
Rubius Therapeutics is focused on creating allogenic cellular therapies harnessing the power of red blood cells for patients with cancer and autoimmune disesases.